Skip navigation

CNBC Stock Blog


Current DateTime: 08:13:18 10 Feb 2012
LinksList Documentid: 25124396
Expiration DateTime: 2/10/2012 8:15:56 PM

ABOUT THE CNBC STOCK BLOG

The CNBC Stock Blog is a cross-section of expert opinions and insights from our TV and Web site coverage. This blog includes posts written by and about top analysts and strategists, super-investors and CNBC's own market mavens. You'll find stock picks, news about publicly-traded companies, commodities, hot sectors, ETFs and the latest options action.
Loading...
Loading...
Loading...
Loading...

RSS FEED

» Help

Current DateTime: 08:13:19 10 Feb 2012
LinksList Documentid: 30328029

CNBC EXPLAINS


Current DateTime: 08:13:19 10 Feb 2012
LinksList Documentid: 44105194

Surging Crude Means Picking Shrewd

Published: Friday, 6 Jun 2008 | 11:52 AM ET
Text Size
By: Andrew Fisher

Big jumps for the unemployment rate and the oil prices on the same morning.  Coincidence?  Not likely, according to Christopher Zook.

"Crude oil, there's a tremendous imbalance right now in supply and demand, as well as the fact that you've got institutional buyers of the commodities trying to hedge out their portfolios against inflationary risk," the chairman and chief investment officer of CAZ Investments told CNBC.  "The reality is, it's stagflation, it's coming, and we saw it this morning."

Recommendations:

So where in the world should a stock-market investment put his money?

"The best idea right now would be Applied Materials [AMAT  Loading...      ()   ]," he said.  "We believe there's a tremendous growth opportunity there in the solar business, as well as the economy begins to recover in 2009 and 2010, they're going to get strength in their core businesses as well."

Zook also likes Procter & Gamble [PG  Loading...      ()   ] and Genentech [DNA  Loading...      ()   ].

"Procter & Gamble we like because of the defensive nature and the consistent performance of that company in an uncertain environment," he said.  "We also like Genentech right now because of the new indications that they're getting for their core drugs; we believe that the valuation is very reasonable for the amount of growth that you're getting in cash flow for that company."

Disclosures:

Disclosure information for Christopher Zook was not immediately available.

Disclaimer

© 2012 CNBC.com


Current DateTime: 10:34:09 10 Feb 2012
LinksList Documentid: 29778428

Current DateTime: 02:33:41 10 Feb 2012
LinksList Documentid: 29779196

Current DateTime: 11:35:13 10 Feb 2012
LinksList Documentid: 29779197

Current DateTime: 02:56:30 10 Feb 2012
LinksList Documentid: 29779199
CNBCCNBC
About CNBC  |  Site Map  |  Video Reprints   |  Advertise  |  Help  |  Contact
Privacy Policy  |     |  Terms of Service  |  Independent Programming Report
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2012 CNBC LLC.  All Rights Reserved.
A Division of NBCUniversal
Thomson ReutersThomson Reuters